Along with the increase in aging of our population, the proportion of older patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) is on the rise as a result of the accumulation of comorbidities as well as biological processes associated with aging. Older patients with acute kidney injury (AKI) comprise an increasing proportion of patients with CKD/ESRD as well. In this review, we will discuss biological processes of aging that predispose patients to AKI and CKD.

Kidney disease has grown into an epidemic, and even more so in the older population. The number of older patients with end-stage renal disease (ESRD) is staggering, which poses a major challenge to the health care system and the community at large. We will review the epidemiology of acute kidney injury (AKI), chronic kidney disease (CKD), and ESRD in older patients, the morphological and functional changes that occur in the kidney with aging, the mechanism of aging and finally the potential therapeutic agents that may play a role in modulating kidney repair in aging.

In 1994, the US Census Bureau reported that the older population (defined here as 65 years and older) was 36.5 million [1]. Subsequent data show that the older population continues to increase, now exceeding 41.5 million, comprising about 18.3% of the total US population [2]. The burden of AKI in the general population is captured by the National Hospital Discharge Survey, National Center for Health Statistics, and indicates that the number of hospitalized patients with a diagnosis of AKI (ICD9 = 584.0-584.9) has increased over the last 20 years, from 161,000 in 1990 to 2.7 million in 2010. This represents ∼7% of hospitalized patients. Prevalence of ESRD increased from 290/million in 1980 to 1,738/million in 2008, an increase of 6,000% [3]. This growth in the older population parallels the increase in the number of older patients with kidney disease. This increase in the overall number of patients with kidney disease is a function of aging. In 2011, among Medicare patients, AKI increased from 14.9/1,000 patient years for patients aged 66-69 years to 18.8, 26.4, 35.9, and 49.6/1,000 patient years for patients aged 70-74, 75-79, 80-84, and >85 years, respectively [3]. Similarly, the prevalence of CKD increased from 5.7 for patients aged 20-39 years to 36.5 for patients >60 years, and the incidence of ESRD increased from 156/million at age 0-19 years, to 127/million at age 20-49 years, and to 571 and 1,307/million for patients aged 45-64 and 65-74 years, respectively [3]. While these data demonstrate that older individuals are more prone to have kidney disease, it is worthwhile to note that in the Baltimore Longitudinal Study, a cohort study conducted between 1958 and 1981 that followed older individuals for 8 or more years, one third of these individuals had no decrease in their renal function, which was measured by creatinine clearance, and a small segment of this population showed improvement in their renal function [4].

While the numbers of glomeruli among individuals range between 250,000 to more than 1.5 million per kidney at birth, it decreases with age at a rate of approximately 6,752 glomeruli/year after the age of 18 years [5]. Renal mass also shows a decrease from >400 g during the 3rd and 4th decade to <300 g by the 9th decade [6]. These morphological changes are usually accompanied by several histological changes in the glomeruli, glomerular basement membrane, tubulointerstitium as well as the renal vasculature. These morphological and histological changes are mirrored by functional changes in these structures [7,8,9]. Table 1 summarizes some of these structural and functional changes noted in the aging kidney.

Table 1

Structural and functional changes in the aging kidney

Structural and functional changes in the aging kidney
Structural and functional changes in the aging kidney

With age, some of the mechanisms required to maintain organ function are impaired, which results in decreased repair capacity. Among the different biological mechanisms that might account for organ aging, somatic senescence has been proposed as a key contributor. The term senescence applies to irreversible growth arrest with viable cells lacking mitogenic stimuli [10]. Thus, while these cells do not necessarily die, their ability to grow is impaired.

Several mechanisms may contribute to senescence occurring with aging. Telomeres are nucleoproteins consisting of repetitive DNA sequences and specific proteins that are located at the end of all eukaryotic chromosomes. Telomeres and telomerase enzymes are thought to play a role in cell senescence [11]. Telomeres are involved in the control of chromosome stability, genetic integrity, and cell viability. When telomeres are damaged or critically short, their protective function is impaired. Telomere shortening forces human primary cells, including endothelial cells, to stop dividing. The enzyme telomerase counteracts the shortening of telomeres [12]. This enzyme contains a catalytic subunit: telomerase reverse transcriptase (TERT). Introduction of TERT into human cells was shown to extend their life span as well as lengthen telomeres to lengths typical of young cells [13,14]. Telomere attrition due to repeated loss and the inability of adult human cells to synthesize de novo telomeres due to the lack of telomerase enzyme occurs with aging and may contribute to cellular senescence. Other cellular stressors suggested as mechanisms of senescence with aging include increases in oxygen radicals, fibrogenic mediators, and mitochondrial injury [15,16]. These mechanisms may cause a shift towards an imbalance in cell repair and proliferation. In the kidney, renal epithelial cell proliferation decreases with aging. At some point, <1% of tubular cells proliferate [17]. This decline in renal epithelial cell proliferation with aging results in the loss of epithelial cells, and hence loss of renal parenchyma [18]. Several genetic, hormonal as well as other mediators increase, and contribute to the cell senescence and decreased capacity of the aging human kidney to cope with abnormal stresses. There is an increase in the cell cycle regulator gene p16INK4A, as well as other mediators such as cyclooxygenase-1, transforming growth factor-β, and p53 [17].

DNA from human kidneys also demonstrates significant telomere loss with aging. The loss of telomeres and DNA repeats at the end of the chromosome results from a lack of telomerase activity and is usually accompanied by cellular senescence [12]. The klotho gene expressed in the kidneys is named after the Greek goddess who spins the thread of life. The klotho mouse whose klotho gene is mutated is characterized by a very short life span. Overexpression of Klotho was shown to extend the life span in the mouse, suggesting a role for this gene as anti-aging gene [19,20].

Aging is associated with impaired adaptive and homeostatic mechanisms leading to cellular senescence and death. Research has focused on attempting to identify agents that can modify cell senescence in the aging kidney (table 2). Reactive oxygen species (ROS) have been implicated in aging. Increased generation of ROS stimulates export of TERT from the nucleus into the cytosol. The antioxidant N-acetyl cysteine reduced intracellular ROS formation and delayed export of TERT and its loss of activity, counteracting the shortening of telomeres and thus delaying senescence, which suggests a role for antioxidants in modulating cell senescence [21]. Similarly, statins affect telomere biology. Statins have the ability to cause overexpression of telomere repeat-binding factor [22]. The removal or loss of this factor leads to telomere dysfunction and triggers apoptosis or senescence. Thus, statins may be beneficial in delaying senescence. Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist that improves insulin-mediated glucose uptake into skeletal muscles, was shown to protect against renal injury in aging. Yang et al. [23] demonstrated that pioglitazone significantly decreased proteinuria, improved creatinine clearance, and significantly ameliorated the development of glomerulosclerosis in aging rats. They suggested that its beneficial actions on the kidney are through increased expression of Klotho and decreased systemic and renal oxidative stress [23].

Table 2

Modify agents of cell senescence in the elder kidney

Modify agents of cell senescence in the elder kidney
Modify agents of cell senescence in the elder kidney

Klotho has antioxidant and anti-inflammatory properties. The klotho gene is expressed primarily in the kidney (distal convoluted tubules) and the choroid plexus of the brain [19].Klotho acts as a coreceptor for FGF23 and plays a role in phosphate and vitamin D metabolism. In addition, Klotho is cleaved by Adams10/17, and the extracellular domain of Klotho is released into the circulation and can act as a hormone to modulate mitochondrial oxidative stress and ameliorate renal injury [24]. Urinary levels of Klotho were shown to be low in several renal disease conditions, including CKD in humans and mice [25] as well as AKI in rats [24], suggesting a potential protective role for Klotho. Whether Klotho has a potential therapeutic role in the aging human kidney remains to be elucidated.

Similarly, studies showed that replacing renal senescent cells with nonsenescent cells [26] and transplantation of old muscle [27] may modify cell senescence in elderly kidneys.

In AKI, more prolonged disease and less successful functional recovery are noted in older patients. AKI is more prevalent in older individuals, mainly due to two reasons: the increased susceptibility of the old kidney to develop AKI and the diminished repair ability of the aging kidney [28,29].

The increased susceptibility of the elderly to develop AKI is due to multiple causes: the structural and functional changes in the aging kidney, as previously discussed, leading to diminished perfusion, excessive interventional procedures, avid use of contrast dye and nephrotoxic drugs such as nonsteroidal anti-inflammatory drugs, as well as the multiple comorbidities that accompany aging. On the other hand, aging affects the normal response of the kidney to acute damage. In response to AKI, cell proliferation and tubule repopulation are inadequate leading to incomplete recovery. The precise mechanism for such age-related inadequacy remains unclear. In comparison to younger patients, 20-30% of older patients who survive AKI fail to completely recover renal function [17]. Hence, identifying therapeutic methods tailored to AKI in older patients is crucial. In the setting of CKD, renal cell damage may trigger the release of cytokines and other signals that may favor maladaptive pathways leading to myofibroblast transformation and glomerular and tubulointerstitial space fibrosis. Glomerular regeneration may involve the division of parietal epithelial cells, located at the glomerulus urinary pole, to produce progenitors that migrate and replace damaged or lost podocytes [30]. Whether similar processes occur following AKI with regression of fibrosis is not known.

Several factors regulate epithelial cell proliferation and thus modify the aging phenotype and accelerate recovery following an acute insult. Zinc-α2 glycoprotein expression was demonstrated to increase following an insult to the mouse kidney with a resultant decrease in epithelial proliferation [31]. In a zinc-α2 glycoprotein knockout rat model, proliferation increases and promotes recovery [31].

Similarly, regeneration of the kidney following ischemia-reperfusion injury in rats was associated with increased levels of mRNA fibrinogen (Fg)α, β and γ [32]. It was further demonstrated that Fgβ-derived Bβ(15-42) peptide administered shortly (1 min) after ischemia reduced reperfusion injury associated with reduced apoptosis and enhanced epithelial cell proliferation 48 h after reperfusion. Taken together, these results suggest a role for Fgβ-derived Bβ(15-42) peptide administration to protect mice from kidney injury induced by ischemia-reperfusion by enhancing epithelial cell proliferation and tissue repair [32].

Following AKI, there is debate as to the source of the cells involved in reconstituting the epithelial cell population [summarized recently in ref. [33,34]]. Potential sources include endogenous surviving epithelial cells, hematopoietic stem cells, or intrarenal stem cells. Bone marrow-derived cells have been shown to engraft minimally in regenerating kidneys following AKI, which suggests that bone marrow-derived cells do not directly repopulate tubules following injury. Cells such as mesenchymal stem cells exert indirect effects to repair injured epithelium through paracrine mechanisms rather than through integration into the kidney parenchyma [35] or through transfer of genetic information to enhance repair [36,37]. Elegant fate mapping studies by Humphreys et al. [38] demonstrate that fully differentiated epithelial cells that survive the injury have the capacity to dedifferentiate, proliferate, and differentiate into epithelial cells. These studies, however, did not rule out the possibility that a minority population of stem cells could have differentiated into epithelial cells. Recent studies have identified a population of proximal tubule cells that are vimentin, CD24, and CD33 positive, and thought to be involved in regeneration following AKI [39]. However, these cells are likely not to be responsible for the majority of repair following AKI, but rather repair is more likely to occur from adjacent surviving epithelial cells that have equivalent capacity to repair [40]. In the aging kidney, the proliferative potential of tubular cells declines with chronological age. The high load of senescent cells in the aged kidney contributes to this decreased proliferative capacity.

Aging, as well as kidney disease in the older patients, is on the rise. Both conditions constitute a burden on the health care system. Understanding the mechanisms of aging and the effects that aging has on the kidney structure and function will serve in identifying therapeutic measures that have the potential of ameliorating some of the changes occurring in the kidneys with aging and hopefully help reverse some of the kidney diseases.

This work was supported by National Institutes of Health grants R01 DK062324 and R01 DK085259.

1.
Spence G: Projections of the population of the United States, by age, sex, and race. Curr Pop Rep 1989, pp 1-17.
2.
US Census Bureau, Current Population Survey: Annual Social and Economic Supplements 2012. www.census.gov.
3.
2013 USRDS Annual Data Report: Atlas of chronic kidney disease and end stage renal disease in the United States. Am J Kidney Dis 2013;63(suppl):e1-e478.
4.
Lindeman RD, Tobin J, Shock NW: Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278-285.
5.
Hoy WE, Douglas-Denton RN, Hughson MD, Cass A, Johnson K, Bertram JF: A stereological study of glomerular number and volume: preliminary findings in a multiracial study of kidneys at autopsy. Kidney Int Suppl 2003;83:S31-S37.
6.
Mulder WJ, Hillen HFP: Renal function and renal disease in the elderly. Part I. Eur J Intern Med 2001;12:86-97.
7.
Anderson S, Brenner BM: Effects of aging on the renal glomerulus. Am J Med 1986;80:435-442.
8.
Hollenberr NK, Adams DF, Solomon HS, Rashid A, Abrams HL, Merrill JP: Senescence and the renal vasculature in normal man. Circ Res 1974;34:309-316.
9.
Baylis C, Corman B: The aging kidney: insights from experimental studies. J Am Soc Nephrol 1998;9:699-709.
10.
Yang H, Fogo AB: Cell senescence in the aging kidney. J Am Soc Nephrol 2010;21:1436-1439.
11.
Schmitt R, Melk A: New insights on molecular mechanisms of renal aging. Am J Transplant 2012;12:2892-2900.
12.
de Lange T: Ending up with the right partner. Nature 1998;392:753-754.
13.
Greider CW, Blackburn EH: Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43:405-413.
14.
Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE: Extension of life-span by introduction of telomerase into normal human cells. Science 1998;279:349-352.
15.
Melk A: Senescence of renal cells: molecular basis and clinical implications. Nephrol Dial Transplant 2003;18:2474-2478.
16.
Percy CJ, Power D, Gobe GC: Renal ageing: changes in the cellular mechanism of energy metabolism and oxidant handling. Nephrology 2008;13:147-152.
17.
Schmitt R, Cantley LG: The impact of aging on kidney repair. Am J Physiol Renal Physiol 2008;294:F1265-F1272.
18.
Gourtsoyiannis N, Prassopoulos P, Cavouras D, Pantelidis N: The thickness of the renal parenchyma decreases with age: a CT study of 360 patients. AJR Am J Roentgenol 1990;155:541-544.
19.
Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51.
20.
Kuro-o M: Klotho and aging. Biochim Biophys Acta 2009;1790:1049-1058.
21.
Haendeler J, Hoffmann J, Diehl JF, Vasa M, Spyridopoulos I, Zeiher AM, Dimmeler S: Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells. Circ Res 2004;94:768-775.
22.
Spyridopoulos I, Haendeler J, Urbich C, Brummendorf TH, Oh H, Schneider MD, Zeiher AM, Dimmeler S: Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 2004;110:3136-3142.
23.
Yang HC, Deleuze S, Zuo Y, Potthoff SA, Ma LJ, Fogo AB: The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. J Am Soc Nephrol 2009;20:2380-2388.
24.
Hu MC, Shi M, Zhang J, Quinones H, Kuro-o M, Moe OW: Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int 2010;78:1240-1251.
25.
Hu MC, Shi M, Zhang J, Quinones H, Griffith C, Kuro-o M, Moe OW: Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011;22:124-136.
26.
Kamminga LM, de Haan G: Cellular memory and hematopoietic stem cell aging. Stem Cells 2006;24:1143-1149.
27.
Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA: Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 2005;433:760-764.
28.
Miura K, Goldstein RS, Morgan DG, Pasino DA, Hewitt WR, Hook JB: Age-related differences in susceptibility to renal ischemia in rats. Toxicol Appl Pharmacol 1987;87:284-296.
29.
Schmitt R, Coca S, Kanbay M, Tinetti ME, Cantley LG, Parikh CR: Recovery of kidney function after acute kidney injury in the elderly: a systematic review and meta-analysis. Am J Kidney Dis 2008;52:262-271.
30.
Li Y, Wingert RA: Regenerative medicine for the kidney: stem cell prospects & challenges. Clin Transl Med 2013;2:11.
31.
Schmitt R, Marlier A, Cantley LG: Zag expression during aging suppresses proliferation after kidney injury. J Am Soc Nephrol 2008;19:2375-2383.
32.
Krishnamoorthy A, Ajay AK, Hoffmann D, Kim TM, Ramirez V, Campanholle G, Bobadilla NA, Waikar SS, Vaidya VS: Fibrinogen β-derived Bβ(15-42) peptide protects against kidney ischemia/reperfusion injury. Blood 2011;118:1934-1942.
33.
Bonventre JV, Yang L: Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011;121:4210-4221.
34.
Humphreys BD: Kidney injury, stem cells and regeneration. Curr Opin Nephrol Hypertens 2014;23:25-31.
35.
Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C: Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005;289:F31-F42.
36.
Bruno S, Grange C, Deregibus MC, Calogero RA, Saviozzi S, Collino F, Morando L, Busca A, Falda M, Bussolati B, Tetta C, Camussi G: Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 2009;20:1053-1067.
37.
Morigi M, Benigni A: Mesenchymal stem cells and kidney repair. Nephrol Dial Transplant 2013;28:788-793.
38.
Humphreys BD, Valerius MT, Kobayashi A, Mugford JW, Soeung S, Duffield JS, McMahon AP, Bonventre JV: Intrinsic epithelial cells repair the kidney after injury. Cell Stem Cell 2008;2:284-291.
39.
Smeets B, Boor P, Dijkman H, Sharma SV, Jirak P, Mooren F, Berger K, Bornemann J, Gelman IH, Floege J, van der Vlag J, Wetzels JF, Moeller MJ: Proximal tubular cells contain a phenotypically distinct, scattered cell population involved in tubular regeneration. J Pathol 2013;229:645-659.
40.
Humphreys BD, Czerniak S, DiRocco DP, Hasnain W, Cheema R, Bonventre JV: Repair of injured proximal tubule does not involve specialized progenitors. Proc Natl Acad Sci USA 2011;108:9226-9231.

Targeting Recovery from Acute Kidney Injury: Round Table Conference at the 19th International Conference on Continuous Renal Replacement Therapies (Manchester Grand Hyatt, San Diego, Calif., USA, March 2-3, 2014).

Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.